Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment

Pharmacokinetic simulations for remdesivir and its metabolites in healthy subjects and patients with renal impairment

IntroductionRemdesivir (RDV) is used for treating COVID-19 patients. This study aims to utilize an in silico pharmacokinetics model to simulate the pharmacokinetics of RDV, its intermediate metabolites (IM), and nucleoside monophosphate (NUC) in both healthy individuals and patients with renal impai...

Full description

Saved in:
Bibliographic Details
Main Authors: Shengjie Zhang, Sunggyeol Jeong, Botao Jiang, Harvey Ho
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
remdesivir
pharmacokinetics
model
renal-impaired
mixed effects
COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1488961/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items